TrialRheumatology (Oxford, England)2020

Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate.

Maxime M A Verhoeven et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.